PMID- 12588291
OWN - NLM
STAT- MEDLINE
DCOM- 20030606
LR  - 20190826
IS  - 0014-2972 (Print)
IS  - 0014-2972 (Linking)
VI  - 33
IP  - 2
DP  - 2003 Feb
TI  - Anti-cardiolipin antibodies in patients with chronic viral hepatitis are 
      independent of beta2-glycoprotein I cofactor or features of antiphospholipid 
      syndrome.
PG  - 161-8
AB  - BACKGROUND: Although controversial, some authorities have implicated hepatitis C 
      virus (HCV) as a cause of anti-phospholipid syndrome (APLS). Anti-cardiolipin 
      antibodies (anti-CLAbs) in APLS are cofactor-dependent ('pathogenic' antibodies). 
      We conducted a study in order to determine the prevalence of anti-CLAbs in HCV 
      patients, and furthermore to address whether these autoantibodies are 
      cofactor-dependent or not and whether they are associated with features of APLS. 
      Patients with hepatitis B virus (HBV) were also evaluated in order to assess 
      whether there are differences in the prevalence and the clinical significance of 
      anti-CLAbs between these two major types of chronic viral hepatitis. MATERIALS 
      AND METHODS: One hundred and seventy-four consecutive HCV patients, 50 HBV 
      patients and 267 healthy were investigated for the presence of anti-CLAbs and 
      antibodies against beta2-glycoprotein I (beta2-GPI), which is the most important 
      cofactor of the 'pathogenic' anti-CLAbs in APLS. IgG anti-CLAbs were determined 
      by an in-house quantitative ELISA and anti-beta2-GPIAbs using a commercial ELISA 
      kit. RESULTS: 21.3% of the HCV and 14% of the HBV patients tested positive for 
      IgG anti-CLAbs (P < 0.0001 compared with healthy controls). Neither age, sex, 
      certain epidemiologic and laboratory parameters nor the clinical status and the 
      histologic findings were associated with anti-CLAbs detection in both diseases. 
      2.3% of the HCV (P < 0.05 compared with healthy controls) and 2% of the HBV 
      patients tested positive for anti-beta2-GPIAbs. Presence of anti-CLAbs was not 
      associated with features of APLS. CONCLUSIONS: A significant proportion of the 
      HCV and HBV patients had detectable IgG anti-CLAbs. However, the anti-CLAbs 
      titres were relatively low, and in most cases seem to be cofactor-independent 
      ('nonpathogenic'). The latter is further supported by the lack of their 
      association with clinical features of APLS. Furthermore, anti-CLAbs appear to be 
      detected irrespective of the demographic, laboratory, clinical and histologic 
      status in both HCV and HBV. However, prospective studies of longer duration may 
      be required in order to address whether anti-CLAbs in patients with chronic viral 
      hepatitis are or are not of clinical importance.
FAU - Zachou, K
AU  - Zachou K
AD  - Department of Internal Medicine, Research Laboratory of Internal Medicine Larisa 
      Medical School, Larisa, Greece.
FAU - Liaskos, C
AU  - Liaskos C
FAU - Christodoulou, D K
AU  - Christodoulou DK
FAU - Kardasi, M
AU  - Kardasi M
FAU - Papadamou, G
AU  - Papadamou G
FAU - Gatselis, N
AU  - Gatselis N
FAU - Georgiadou, S P
AU  - Georgiadou SP
FAU - Tsianos, E V
AU  - Tsianos EV
FAU - Dalekos, G N
AU  - Dalekos GN
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Autoantibodies)
RN  - 0 (Glycoproteins)
RN  - 0 (Immunoglobulin G)
RN  - 0 (beta 2-Glycoprotein I)
SB  - IM
MH  - Abortion, Habitual/immunology/virology
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Anticardiolipin/*blood
MH  - Antiphospholipid Syndrome/immunology/*virology
MH  - Autoantibodies/blood
MH  - Female
MH  - Glycoproteins/*immunology
MH  - Hepatitis B, Chronic/complications/immunology
MH  - Hepatitis C, Chronic/*complications/immunology
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Male
MH  - Middle Aged
MH  - Pregnancy
MH  - Thrombocytopenia/immunology/virology
MH  - beta 2-Glycoprotein I
EDAT- 2003/02/18 04:00
MHDA- 2003/06/07 05:00
CRDT- 2003/02/18 04:00
PHST- 2003/02/18 04:00 [pubmed]
PHST- 2003/06/07 05:00 [medline]
PHST- 2003/02/18 04:00 [entrez]
AID - 1110 [pii]
AID - 10.1046/j.1365-2362.2003.01110.x [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2003 Feb;33(2):161-8. doi: 10.1046/j.1365-2362.2003.01110.x.